The Oral Solid Dosage Contract Manufacturing Market supports pharmaceutical companies by providing specialized production capabilities for tablets, capsules, granules, powders, and related oral solid products. As APIs have grown more complex, creative formulations that efficiently deliver drugs to target sites have become essential. Oral solid dose forms remain unmatched in importance; almost two-thirds of prescription medications worldwide are administered as oral solids. These dosage forms offer affordability, stability, and patient-centric advantages that support adherence.

Oral Solid Dosage Contract Manufacturing Market size was valued at USD 10.07 billion in 2025. The market is anticipated to grow from USD 10.99 billion in 2026 to USD 22.62 billion by 2034, exhibiting a CAGR of 9.4% during the forecast period.

Formulation Development and Manufacturing Processes

OSD contract manufacturers deliver services spanning product development through commercial production. These include formulation development, process development, scale-up, and technology transfer. Based on product requirements, manufacturers handle granulation, tablet compression, capsule filling, and coating. Packaging, labeling, and quality testing are integral components. Some CDMOs also provide regulatory and quality support across different markets. Effective OSD formulation development allows pharmaceutical companies to leverage specialized facilities and expertise without managing every step internally.

Core process steps begin with selection and testing of the API and excipients. Mixing and granulation improve flow and compressibility. The material then undergoes granulation and tablet compression or capsule filling. Coating may be applied for protection or modified release. Quality testing confirms strength, purity, and performance before packaging and serialization. This structured approach ensures consistency and regulatory compliance throughout production. 

Mechanism Segments and Emerging Capabilities

While controlled release held 43.50% of market revenue in 2025, the immediate release segment is expected to grow at a CAGR of 8.50% during the forecast period. Immediate release dosage forms release the active ingredient soon after administration and are widely used for treatments requiring quick action. Their relatively simple production process supports demand from pharmaceutical manufacturers. Delayed release addresses specific therapeutic needs.

Advances in drug delivery and complex formulations create opportunities for CDMOs with specialized skills. Recipharm’s pilot plant, opened in 2025, supports single- and dual-fill capsules, advanced tablet manufacturing, and both dry and wet granulation. These capabilities enable support from early development through small-scale commercial production. In addition, fixed-dose combination manufacturing is gaining attention. Piramal Pharma Solutions and NewAmsterdam Pharma opened a dedicated OSD suite in Pennsylvania in August 2025 that supports fixed-dose combination products and includes granulation, compression, tableting, and coating capabilities. Dual-sourcing options through facilities in India further enhance supply flexibility.

Regulatory Considerations and Quality Focus

Regulatory and quality challenges remain a restraint. Different markets may impose varying testing, documentation, validation, and product-release rules. Manufacturers must maintain batch-to-batch consistency; any material or process change can trigger additional checks that add time and cost. Consequently, pharmaceutical companies actively seek partners with proven track records of regulatory compliant manufacturing. Investment in quality management systems, reliable documentation procedures, and adherence to global regulatory norms allows OSD contract manufacturers to differentiate themselves.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/oral-solid-dosage-contract-manufacturing-market

Competitive Landscape and Recent Developments

Key participants in the Oral Solid Dosage Contract Manufacturing Market include AbbVie Contract Manufacturing, Aenova Group, Alkem Laboratories Limited, Catalent, Inc., Dr. Reddy's Laboratories, Evonik, Famar, Granules India Limited, Jubilant Pharmova Limited, Lonza, Patheon Pharma Services (Thermo Fisher Scientific), Pfizer CentreOne, Piramal Pharma Solutions, Recipharm AB, and Vetter Pharma. Recent activity underscores continued investment. In March 2026, Forma Life Sciences launched as an independent CDMO focused on oral solid dosage development and manufacturing in the U.S., offering formulation development, clinical manufacturing, and commercial production. In February 2026, Piramal Pharma Solutions introduced commercial tablet-in-capsule technology supporting dual-release and combination drug formulations.

Looking ahead, outsourcing is expected to remain important as drug makers seek flexible production support. Generic drug demand will continue to underpin OSD manufacturing volumes. Complex formulations and regional manufacturing strategies aimed at supply-chain resilience will open further opportunities. Companies that combine strong OSD formulation development, reliable granulation and tablet compression capabilities, expertise in fixed-dose combination manufacturing, and consistent regulatory compliant manufacturing practices are well positioned to support the evolving needs of pharmaceutical sponsors.

More Trending Latest Reports By Polaris Market Research:

ai-data-center-market

collagen-market

genealogy-products-and-services-market

data-center-liquid-cooling-fluids-market

antibody-discovery-market

water-heater-market

anti-obesity-medication-market

commercial-aircraft-aftermarket-parts-industry

leading-10-companies-transforming-e-commerce-logistics-market-2025